MIRCERA ® prefilled syringe with the needle is placed in a medication blister pack. It consists of four safety features as depicted below – plunger, release clips, finger flanges and needle guard. Avoid contact with the release clips to keep from activating the safety device prematurely.

MIRCERA ® is indicated for the treatment of anemia associated with CKD in adult patients on dialysis and adult patients not on dialysis. Prefilled syringes are not designed for administration of partial doses. Round doses to the closest dose achievable with the prefilled syringes.

ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS and TUMOR PROGRESSION OR RECURRENCE.

MIRCERA is indicated for the treatment of anaemia associated with chronic kidney disease (CKD). Adult patients on dialysis and adult patients not on dialysis. MIRCERA is administered less frequently than other erythropoiesis stimulating agents (ESAs) due to …

Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in: • adult patients on dialysis and adult patients not on dialysis. • pediatric patients 3 months to...

Jun 26, 2024 · What is Mircera? Mircera injection is an erythropoiesis-stimulating agent (ESA) that contains epoetin beta and methoxy polyethylene glycol which may be used to treat anemia associated with chronic kidney disease (CKD) in: adults on dialysis and not on dialysis

1. Methoxy polyethylene glycol-epoetin (Mircera ®) will be increased and decreased in 1-step or 2-step increments, based on scale above. 2. Mircera ® will be administered IV to in-center hemodialysis patients, and SQ to home dialysis patients. 3. Mircera® ceiling is 200 mcg every two weeks (or 3.0 mcg/kg every 2 weeks, whichever is lower).

MIRCERA ® is a Continuous Erythropoetin Receptor Activator (C.E.R.A.) indicated for: the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients.

MIRCERA is indicated for the treatment of anemia associated with chronic kidney disease (CKD) including patients on dialysis and patients not on dialysis. MIRCERA is administered less frequently than other erythropoiesis stimulating agents (ESAs) due to …

Mircera is indicated for the treatment of anaemia associated with chronic kidney disease (CKD). Use the lowest dose of Mircera that will gradually increase the haemoglobin concentration. Mircera is administered less frequently than Aranesp®, Eprex® and NeoRecormon® due to the longer elimination half-life.